NEW YORK (GenomeWeb) – Interpace Diagnostics said today that Premera Blue Cross, a regional health plan, has agreed to cover its ThyraMIR test for more than 2 million members located primarily in Washington, Oregon, and Alaska.

Premera Blue Cross has a network of more than 38,000 physicians, hospitals, laboratories, and other healthcare providers across the Northwest, Interpace said.

Its ThyraMIR assay is covered for thyroid nodules deemed indeterminate by standard cytopathological analysis.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.